Health & Fitness
Health and Fitness
Health and Fitness
Thu, September 3, 2009Wed, September 2, 2009Tue, September 1, 2009Mon, August 31, 2009Fri, August 28, 2009Thu, August 27, 2009Wed, August 26, 2009Tue, August 25, 2009Mon, August 24, 2009Sun, August 23, 2009Fri, August 21, 2009Thu, August 20, 2009Wed, August 19, 2009Tue, August 18, 2009Mon, August 17, 2009Sun, August 16, 2009Fri, August 14, 2009Thu, August 13, 2009Wed, August 12, 2009Tue, August 11, 2009Mon, August 10, 2009Fri, August 7, 2009Thu, August 6, 2009Wed, August 5, 2009Tue, August 4, 2009Mon, August 3, 2009Sat, August 1, 2009Fri, July 31, 2009Thu, July 30, 2009Wed, July 29, 2009Tue, July 28, 2009Mon, July 27, 2009Sat, July 25, 2009Fri, July 24, 2009Thu, July 23, 2009Wed, July 22, 2009Tue, July 21, 2009Mon, July 20, 2009Sun, July 19, 2009Fri, July 17, 2009Thu, July 16, 2009Wed, July 15, 2009Tue, July 14, 2009Mon, July 13, 2009Fri, July 10, 2009Thu, July 9, 2009Altair Nanotechnologies, Inc. : Altairnano Assigns Renazorb(TM) and Renalan(TM) Patents to Spectrum Pharmaceuticals
Published in Health and Fitness on Thursday, August 6th 2009 at 3:41 GMT, Last Modified on 2009-08-06 03:41:09 by Market Wire
RENO, NV--(Marketwire - August 6, 2009) - Altair Nanotechnologies, Inc. (Altairnano) (
Under terms of the agreement, Altairnano will receive $750,000 in Spectrum Pharmaceuticals restricted common stock. In addition to the royalty and other payments Altairnano was to receive under the prior license agreement Altairnano will now receive 10% of any fees Spectrum Pharmaceuticals may receive from the sublicensing of Renazorb™, Renalan™, and any related compounds.
Renazorb™ products were designed to support phosphate control in patients with Chronic Kidney Disease, hyperphosphatemia, and high phosphate levels in blood, associated with End Stage Renal Disease. The proprietary lanthanum nanomaterial technology was developed by Altairnano to support the company's Life Sciences division. In Q1 2009, Altairnano announced its intent to reduce resources and the financial requirements necessary for supporting market applications associated with the company's Life Sciences division.
"Altairnano is focused on designing, manufacturing, and selling power and energy management systems to the utility, transportation, and military sectors," said Terry Copeland. "Today's announcement reflects this commitment, while allowing Altairnano to recognize immediate value from research and patents associated with our former Life Sciences division."
All patents associated with Renazorb™ and Renalan™ will be assigned to Spectrum Pharmaceuticals. Spectrum Pharmaceuticals will assume responsibility for ongoing maintenance and prosecution of the patents.
About Altair Nanotechnologies, Inc.
Headquartered in Reno, Nevada with manufacturing in Anderson, Indiana, Altairnano is a leading provider of energy storage systems for clean, efficient power and energy management. Going beyond lithium ion, Altairnano's Lithium-Titanate based battery systems are among the highest performing and most scalable, with applications that include battery cells for military artillery, battery packs for hybrid vehicles and energy storage systems for large-scale stationary power services. For more information please visit Altairnano at [ www.altairnano.com ].
Forward-Looking Statements
This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the company's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that development of the advanced lithium ion-based batteries and related products described herein will not be completed for technical, political, strategic or other reasons; that any products developed will not perform as expected in future testing or real-world applications; and that even if full commercialization occurs, product sales may be limited and costs associated with production may exceed revenues. In addition, other risks are identified in the company's most recent Annual Report on Form 10-K and Form 10-Q, as filed with the SEC. Such forward-looking statements speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.
